Article
Highlights From Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Held In May 2018
On May 18, 2018, the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) concluded two referrals for Zinbryta (daclizumab beta) and Esmya (ulipristal acetate) ...

S&A Law Offices



